1. Home
  2. LND vs LYEL Comparison

LND vs LYEL Comparison

Compare LND & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil)

LND

Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil)

HOLD

Current Price

$3.81

Market Cap

353.6M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$17.35

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LND
LYEL
Founded
2005
2018
Country
Brazil
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.6M
401.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LND
LYEL
Price
$3.81
$17.35
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
77.2K
51.8K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
3.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$1.65
N/A
Revenue Next Year
$6.42
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.47
$0.40
52 Week High
$4.45
$45.00

Technical Indicators

Market Signals
Indicator
LND
LYEL
Relative Strength Index (RSI) 45.56 36.48
Support Level $3.77 $17.34
Resistance Level $4.29 $19.02
Average True Range (ATR) 0.09 1.22
MACD 0.01 -0.21
Stochastic Oscillator 46.55 34.78

Price Performance

Historical Comparison
LND
LYEL

About LND Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil)

Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: